The miRNA journey from theory to practice as a CNS biomarker

Frontiers in Genetics

Volumn 7, Issue FEB, 2016, Pages

  Stoicea, Nicoleta ^a   Du, Amy ^b   Lakis, Christie D ^b   Tipton, Courtney ^b   Arias Morales, Carlos E ^a   Bergese, Sergio D ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

Author keywords

Biomarker; Central nervous system (CNS); Cerebrospinal fluid (CSF); MicroRNA; Neurodegenerative disease

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 8; MICRORNA; MICRORNA 107; MICRORNA 125B; MICRORNA 132 3P; MICRORNA 132 5P; MICRORNA 143 3P; MICRORNA 143 5P; MICRORNA 181C; MICRORNA 21; MICRORNA 210; MICRORNA 216A; MICRORNA 26B; MICRORNA 27A; MICRORNA 29A; MICRORNA 338 3P; MICRORNA 633; MICRORNA 802; MICRORNA 9; MICRORNA 922; MICRORNA LET 7B; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ALZHEIMER DISEASE; AMYOTROPHIC LATERAL SCLEROSIS; CENTRAL NERVOUS SYSTEM TUMOR; CEREBROSPINAL FLUID ANALYSIS; DIAGNOSTIC PROCEDURE; DNA TRANSCRIPTION; GENE EXPRESSION; GENE EXPRESSION REGULATION; HUMAN; META ANALYSIS (TOPIC); MULTIPLE SCLEROSIS; NEUROLOGIC DISEASE; PARKINSON DISEASE; PATHOGENESIS; REVIEW; TRAUMATIC BRAIN INJURY;

EID: 84962514463     PISSN: None     EISSN: 16648021     Source Type: Journal    
DOI: 10.3389/fgene.2016.00011     Document Type: Review

References (81)

1. Ackermann, W., Stoicea, N., Wojda, T. R., Steiner, N., Barnett, C. J., and Bergese, S. D. (2014). Does post-operative cognitive decline promote/accelerate Alzheimer's disease pathology? Perioperative cerebrospinal fluid biomarkers and the gap of knowledge. Aust. J. Anesth. Anal. 2:1038.
2. Akers, J. C., Ramakrishnan, V., Kim, R., Skog, J., Nakano, I., Pingle, S., et al. (2013). MiR-21 in the extracellular vesicles (EVs) of cerebrospinal fluid (CSF): a platform for glioblastoma biomarker development. PLoS ONE 8:e78115. doi: 10.1371/journal.pone.0078115
3. Alexandrov, P. N., Dua, P., Hill, J. M., Bhattacharjee, S., Zhao, Y., and Lukiw, W. J. (2012). microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). Int. J. Biochem. Mol. Biol. 3, 365-373.
4. Aschrafi, A., Schwechter, A. D., Mameza, M. G., Natera-Naranjo, O., Gioio, A. E., and Kaplan, B. B. (2008). MicroRNA-338 regulates local cytochrome c oxidase IV mRNA levels and oxidative phosphorylation in the axons of sympathetic neurons. J. Neurosci. 28, 12581-12590. doi: 10.1523/JNEUROSCI.3338-08.2008
5. Balakathiresan, N., Bhomia, M., Chandran, R., Chavko, M., McCarron, R. M., and Maheshwari, R. K. (2012). MicroRNA let-7i is a promising serum biomarker for blast-induced traumatic brain injury. J. Neurotrauma 29, 1379-1387. doi: 10.1089/neu.2011.2146
6. Baraniskin, A., Kuhnhenn, J., Schlegel, U., Chan, A., Deckert, M., Gold, R., et al. (2011). Identification of microRNAs in the cerebrospinal fluid as marker for primary diffuse large B-cell lymphoma of the central nervous system. Blood 117, 3140-3146. doi: 10.1182/blood-2010-09-308684
7. Baraniskin, A., Kuhnhenn, J., Schlegel, U., Maghnouj, A., Zöllner, H., Schmiegel, W., et al. (2012b). Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. Neuro-oncology 14, 29-33. doi: 10.1093/neuonc/nor169
8. Baraniskin, A., Kuhnhenn, J., Schlegel, U., Schmiegel, W., Hahn, S., and Schroers, R. (2012a). MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma. J. Neurooncol. 109, 239-244. doi: 10.1007/s11060-012-0908-2
9. Begley, D. J., and Brightman, M. W. (2003). Structural and functional aspects of the blood-brain barrier. Prog. Drug Res. 6, 19-78. doi: 10.1007/978-3-0348-8049-7_2
10. Berzin, T. M., Zipser, B. D., Rafii, M. S., Kuo-Leblanc, V., Yancopoulos, G. D., Glass, D. J., et al. (2000). Agrin and microvascular damage in Alzheimer's disease. Neurobiol. Aging 21, 349-355. doi: 10.1016/S0197-4580(00)00121-4
11. Blennow, K., Wallin, A., Fredman, P., Karlsson, I., Gottfries, C. G., and Svennerholm, L. (1990). Blood-brain barrier disturbance in patients with Alzheimer's disease is related to vascular factors. Acta Neurol. Scand. 81, 323-326. doi: 10.1111/j.1600-0404.1990.tb01563.x
12. Bonauer, A., Boon, R. A., and Dimmeler, S. (2010). Vascular micrornas. Curr. Drug Targets 11, 943-949. doi: 10.2174/138945010791591313
13. Brinkmalm, A., Brinkmalm, G., Honer, W. G., Frölich, L., Hausner, L., Minthon, L., et al. (2014). SNAP-25 is a promising novel cerebrospinal fluid biomarker for synapse degeneration in Alzheimer's disease. Mol. Neurodegener. 9:53. doi: 10.1186/1750-1326-9-53
14. Burgos, K. L., Javaherian, A., Bomprezzi, R., Ghaffari, L., Rhodes, S., Courtright, A., et al. (2013). Identification of extracellular miRNA in human cerebrospinal fluid by next-generation sequencing. RNA 19, 712-722. doi: 10.1261/rna.036863.112
15. Burgos, K., Malenica, I., Metpally, R., Courtright, A., Rakela, B., Beach, T., et al. (2014). Profiles of extracellular miRNA in cerebrospinal fluid and serum from patients with Alzheimer's and Parkinson's diseases correlate with disease status and features of pathology. PLoS ONE 9:e94839. doi: 10.1371/journal.pone.0094839
16. Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S., Noch, E., et al. (2002). Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc. Natl. Acad. Sci. U.S.A. 99, 15524-15529. doi: 10.1073/pnas.242606799
17. Chan, A. W., and Kocerha, J. (2012). The path to microRNA therapeutics in psychiatric and neurodegenerative disorders. Front. Genet. 3:82. doi: 10.3389/fgene.2012.00082
18. Cheng, L., Quek, C. Y., Sun, X., Bellingham, S. A., and Hill, A. F. (2013). The detection of microRNA associated with Alzheimer's disease in biological fluids using next-generation sequencing technologies. Front. Genet. 4:150. doi: 10.3389/fgene.2013.00150
19. Cloutier, F., Marrero, A., O'Connell, C., and Morin, P., Jr. (2015). MicroRNAs as potential circulating biomarkers for amyotrophic lateral sclerosis. J. Mol. Neurosci. 56, 102-112. doi: 10.1007/s12031-014-0471-8
20. Cogswell, J. P., Ward, J., Taylor, I. A., Waters, M., Shi, Y., Cannon, B., et al. (2008). Identification of miRNA changes in Alzheimer's disease brain and CSF yields putative biomarkers and insights into disease pathways. J. Alzheimers Dis. 14, 27-41.
21. Czeiter, E., Mondello, S., Kovacs, N., Sandor, J., Gabrielli, A., Schmid, K., et al. (2012). Brain injury biomarkers may improve the predictive power of the IMPACT outcome calculator. J. Neurotrauma 29, 1770-1778. doi: 10.1089/neu.2011.2127
22. De Felice, B., Annunziata, A., Fiorentino, G., Borra, M., Biffali, E., Coppola, C., et al. (2014). miR-338-3p is over-expressed in blood, CFS, serum and spinal cord from sporadic amyotrophic lateral sclerosis patients. Neurogenetics 15, 243-253. doi: 10.1007/s10048-014-0420-2
23. De Smaele, E., Ferretti, E., and Gulino, A. (2010). MicroRNAs as biomarkers for CNS cancer and other disorders. Brain Res. 133, 800-811. doi: 10.1016/j.brainres.2010.03.103
24. Eldh, M., Lötvall, J., Malmhäll, C., and Ekström, K. (2012). Importance of RNA isolation methods for analysis of exosomal RNA: evaluation of different methods. Mol. Immunol. 50, 278-286. doi: 10.1016/j.molimm.2012.02.001
25. Ferretti, E., De Smaele, E., Miele, E., Laneve, P., Po, A., Pelloni, M., et al. (2008). Concerted microRNA control of Hedgehog signalling in cerebellar neuronal progenitor and tumour cells. EMBO J. 27, 2616-2627. doi: 10.1038/emboj.2008.172
26. Freischmidt, A., Müller, K., Ludolph, A. C., and Weishaupt, J. H. (2013). Systemic dysregulation of TDP-43 binding microRNAs in amyotrophic lateral sclerosis. Acta Neuropathol. Commun. 1:42. doi: 10.1186/2051-5960-1-42
27. Gabriely, G., Wurdinger, T., Kesari, S., Esau, C. C., Burchard, J., Linsley, P. S., et al. (2008). MicroRNA 21 promotes glioma invasion by targeting matrix metalloproteinase regulators. Mol. Cell. Biol. 28, 5369-5380. doi: 10.1128/MCB.00479-08
28. Galimberti, D., Villa, C., Fenoglio, C., Serpente, M., Ghezzi, L., Cioffi, S. M., et al. (2014). Circulating miRNAs as potential biomarkers in Alzheimer's disease. J. Alzheimers. Dis. 42, 1261-1267. doi: 10.1016/j.jalz.2014.05.278
29. Gallego, J. A., Gordon, M. L., Claycomb, K., Bhatt, M., Lencz, T., and Malhotra, A. K. (2012). In vivo microRNA detection and quantitation in cerebrospinal fluid. J. Mol. Neurosci. 47, 243-248. doi: 10.1007/s12031-012-9731-7
30. Garber, M., Grabherr, M. G., Guttman, M., and Trapnell, C. (2011). Computational methods for transcriptome annotation and quantification using RNA-seq. Nat. Methods 8, 469-477. doi: 10.1038/nmeth.1613
31. Ghidoni, R., Benussi, L., Paterlini, A., Albertini, V., Binetti, G., and Emanuele, E. (2011). Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future. Neurodegener. Dis. 8, 413-420. doi: 10.1159/000327756
32. Guan, Y., Mizoguchi, M., Yoshimoto, K., Hata, N., Shono, T., Suzuki, S. O., et al. (2010). MiRNA-196 is upregulated in glioblastoma but not in anaplastic astrocytoma and has prognostic significance. Clin. Cancer Res. 16, 4289-4297. doi: 10.1158/1078-0432.CCR-10-0207
33. Haghikia, A., Haghikia, A., Hellwig, K., Baraniskin, A., Holzmann, A., Decard, B. F., et al. (2012). Regulated microRNAs in the CSF of patients with multiple sclerosis: a case-control study. Neurology 79, 2166-2170. doi: 10.1212/WNL.0b013e3182759621
34. Hébert, S. S., Horré, K., Nicolaï, L., Papadopoulou, A. S., Mandemakers, W., Silahtaroglu, A. N., et al. (2008). Loss of microRNA cluster miR-29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase expression. Proc. Natl. Acad. Sci. U.S.A. 105, 6415-6420. doi: 10.1073/pnas.0710263105
35. Hoglund, K., Fourier, A., Perret-Liaudet, A., Zetterberg, H., Blennow, K., and Portelius, E. (2015). Alzheimer's disease-Recent biomarker developments in relation to updated diagnostic criteria. Clin. Chim. Acta 44, 9-8. doi: 10.1016/j.cca.2015.01.041
36. Humpel, C. (2011). Identifying and validating biomarkers for Alzheimer's disease. Trends Biotechnol. 29, 26-32. doi: 10.1016/j.tibtech.2010.09.007
37. Kern, S., Skoog, I., Borjesson-Hanson, A., Blennow, K., Zetterberg, H., Ostling, S., et al. (2014). Higher CSF interleukin-6 and CSF interleukin-8 in current depression in older women. Results from a population-based sample. Brain Behav. Immun. 4, 15-18. doi: 10.1016/j.bbi.2014.05.006
38. Kiko, T., Nakagawa, K., Tsuduki, T., Furukawa, K., Arai, H., and Miyazawa, T. (2014). MicroRNAs in plasma and cerebrospinal fluid as potential markers for Alzheimer's disease. J. Alzheimers. Dis. 39, 253-259. doi: 10.3233/JAD-130932
39. Kim, D. H., Yeo, S. H., Park, J. M., Choi, J. Y., Lee, T. H., Park, S. Y., et al. (2014). Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene 545, 185-193. doi: 10.1016/j.gene.2014.05.031
40. Kolshus, E., Dalton, V. S., Ryan, K. M., and McLoughlin, D. M. (2014). When less is more-microRNAs and psychiatric disorders. Acta Psychiatr. Scand. 129, 241-256. doi: 10.1111/acps.12191
41. Ksiazek-Winiarek, D. J., Kacperska, M. J., and Glabinski, A. (2013). MicroRNAs as novel regulators of neuroinflammation. Mediators Inflamm. 201, 372351. doi: 10.1155/2013/172351
42. Kvartsberg, H., Duits, F. H., Ingelsson, M., Andreasen, N., Öhrfelt, A., Andersson, K., et al. (2014). Cerebrospinal fluid levels of the synaptic protein neurogranin correlates with cognitive decline in prodromal Alzheimer's disease. Alzheimers Dement. 11, 1180-1190. doi: 10.1016/j.jalz.2014.10.009
43. Lehmann, S. M., Krüger, C., Park, B., Derkow, K., Rosenberger, K., Baumgart, J., et al. (2012). An unconventional role for miRNA: let-7 activates Toll-like receptor 7 and causes neurodegeneration. Nat. Neurosci. 15, 827-835. doi: 10.1038/nn.3113
44. Liu, P., Li, Y. W., Wang, X. S., Zou, X., Zhang, D. Z., Wang, D. X., et al. (2013). High serum interleukin-6 level is associated with increased risk of delirium in elderly patients after noncardiac surgery: a prospective cohort study. Chin. Med. J. 126, 3621-3627.
45. Liu, S. C., Chuang, S. M., Hsu, C. J., Tsai, C. H., Wang, S. W., and Tang, C. H. (2014). CTGF increases vascular endothelial growth factor-dependent angiogenesis in human synovial fibroblasts by increasing miR-210 expression. Cell Death Dis. 5:e1485. doi: 10.1038/cddis.2014.453
46. Maxeiner, H. G., Marion Schneider, E., Kurfiss, S. T., Brettschneider, J., Tumani, H., and Bechter, K. (2014). Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine 69, 62-67. doi: 10.1016/j.cyto.2014.05.008
47. Medina, P. P., Nolde, M., and Slack, F. J. (2010). OncomiR addiction in an in vivo model of microRNA-21-induced pre-B-cell lymphoma. Nature 467, 86-90. doi: 10.1038/nature09284
48. Meyer, S. U., Pfaffl, M. W., and Ulbrich, S. E. (2010). Normalization strategies for microRNA profiling experiments: a 'normal' way to a hidden layer of complexity? Biotechnol. Lett. 32, 1777-1788. doi: 10.1007/s10529-010-0380-z
49. Müller, M., Jäkel, L., Bruinsma, I. B., Claassen, J. A., Kuiperij, H. B., and Verbeek, M. M. (2015). MicroRNA-29a is a candidate biomarker for Alzheimer's disease in cell-free cerebrospinal fluid. Mol. Neurobiol. doi: 10.1007/s12035-015-9156-8. [Epub ahead of print].
50. Oved, K., Morag, A., Pasmanik-Chor, M., Rehavi, M., Shomron, N., and Gurwitz, D. (2013). Genome-wide expression profiling of human lymphoblastoid cell lines implicates integrin beta-3 in the mode of action of antidepressants. Transl. Psychiatry 3:e313. doi: 10.1038/tp.2013.86
51. Pacifici, M., Delbue, S., Ferrante, P., Jeansonne, D., Kadri, F., Nelson, S., et al. (2013). Cerebrospinal fluid miRNA profile in HIV-encephalitis. J. Cell. Physiol. 228, 1070-1075. doi: 10.1002/jcp.24254
52. Patz, S., Trattnig, C., Grunbacher, G., Ebner, B., Gülly, C., Novak, A., et al. (2013). More than cell dust: microparticles isolated from cerebrospinal fluid of brain injured patients are messengers carrying mRNAs, miRNAs, and proteins. J. Neurotrauma 30, 1232-1242. doi: 10.1089/neu.2012.2596
53. Polman, C. H., Reingold, S. C., Edan, G., Filippi, M., Hartung, H. P., Kappos, L., et al. (2005). Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria." Ann. Neurol. 58, 840-846. doi: 10.1002/ana.20703
54. Pritchard, C. C., Cheng, H. H., and Tewari, M. (2012). MicroRNA profiling: approaches and considerations. Nat. Rev. Genet. 13, 358-369. doi: 10.1038/nrg3198
55. Pyykö, O., Lumela, M., Rummukainen, J., Nerg, O., Seppälä, T. T., Herukka, S., et al. (2014). Cerebrospinal fluid biomarker and brain biopsy findings in idiopathic normal pressure hydrocephalus. PLoS ONE 9:e91974. doi: 10.1371/journal.pone.0091974
56. Qu, S., Guan, J., and Liu, Y. (2015). Identification of microRNAs as novel biomarkers for glioma detection: a meta-analysis based on 11 articles. J. Neurol. Sci. 348, 181-187. doi: 10.1016/j.jns.2014.11.036
57. Ragusa, M., Majorana, A., Banelli, B., Barbagallo, D., Statello, L., Casciano, I., et al. (2010). MIR152, MIR200B, and MIR338, human positional and functional neuroblastoma candidates, are involved in neuroblast differentiation and apoptosis. J. Mol. Med. 88, 1041-1053. doi: 10.1007/s00109-010-0643-0
58. Rao, P., Benito, E., and Fischer, A. (2013). MicroRNAs as biomarkers for CNS disease. Front. Mol. Neurosci. 6:39. doi: 10.3389/fnmol.2013.00039
59. Robertus, J. L., Harms, G., Blokzijl, T., Booman, M., de Jong, D., van Imhoff, G., et al. (2009). Specific expression of miR-17-5p and miR-127 in testicular and central nervous system diffuse large B-cell lymphoma. Mod. Pathol. 22, 547-555. doi: 10.1038/modpathol.2009.10
60. Rosén, C., Farahmand, B., Skillbäck, T., Nägga, K., Mattsson, N., Kilander, L., et al. (2015). Benchmarking biomarker-based criteria for Alzheimer's disease: data from the Swedish Dementia Registry, SveDem. Alzheimers Dement. 11, 1470-1479. doi: 10.1016/j.jalz.2015.04.007
61. Ruggeri, B., Sarkans, U., Schumann, G., and Persico, A. M. (2014). Biomarkers in autism spectrum disorder: the old and the new. Psychopharmacology 231, 1201-1216. doi: 10.1007/s00213-013-3290-7
62. Sala Frigerio, C., Lau, P., Salta, E., Tournoy, J., Bossers, K., Vandenberghe, R., et al. (2013). Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease. Neurology 81, 2103-2106. doi: 10.1212/01.wnl.0000437306.37850.22
63. Schramedei, K., Mörbt, N., Pfeifer, G., Läuter, J., Rosolowski, M., Tomm, J. M., et al. (2011). MicroRNA-21 targets tumor suppressor genes ANP32A and SMARCA4. Oncogene 30, 2975-2985. doi: 10.1038/onc.2011.15
64. Scollato, A., Terreni, A., Caldini, A., Salvadori, B., Gallina, P., Francese, S., et al. (2010). CSF proteomic analysis in patients with normal pressure hydrocephalus selected for the shunt: CSF biomarkers of response to surgical treatment. Neurol. Sci. 31, 283-291. doi: 10.1007/s10072-009-0181-0
65. Sheinerman, K. S., and Umansky, S. R. (2013). Circulating cell-free microRNA as biomarkers for screening, diagnosis and monitoring of neurodegenerative diseases and other neurologic pathologies. Front. Cell. Neurosci. 7:150. doi: 10.3389/fncel.2013.00150
66. Shioya, M., Obayashi, S., Tabunoki, H., Arima, K., Saito, Y., Ishida, T., et al. (2010). Aberrant microRNA expression in the brains of neurodegenerative diseases: miR-29a decreased in Alzheimer disease brains targets neurone navigator 3. Neuropathol. Appl. Neurobiol. 36, 320-330. doi: 10.1111/j.1365-2990.2010.01076.x
67. Siegel, S. R., Mackenzie, J., Chaplin, G., Jablonski, N. G., and Griffiths, L. (2012). Circulating microRNAs involved in multiple sclerosis. Mol. Biol. Rep. 39, 6219-6225. doi: 10.1007/s11033-011-1441-7
68. Solerte, S. B., Ferrari, E., Cuzzoni, G., Locatelli, E., Giustina, A., Zamboni, M., et al. (2005). Decreased release of the angiogenic peptide vascular endothelial growth factor in Alzheimer's disease: recovering effect with insulin and DHEA sulfate. Dement. Geriatr. Cogn. Disord. 19, 1-10. doi: 10.1159/000080963
69. Sørensen, S., Nygaard, A.-B., Nielsen, M.-Y., Jensen, K., and Christensen, T. (2014). miRNA expression profiles in cerebrospinal fluid and blood of patients with acute ischemic stroke. Transl. Stroke Res. 5, 711-718. doi: 10.1007/s12975-014-0364-8
70. Stoicea, N., Wilson, T., Chandrasekhar, K., and Bergese, S. D. (2013). The role of microRNAs as potential biomarkers in central nervous system disorders. Int. J. Clin. Anesthesiol. 1:1009. doi: 10.3389/fnmol.2013.00039
71. Teplyuk, N. M., Mollenhauer, B., Gabriely, G., Giese, A., Kim, E., Smolsky, M., et al. (2012). MicroRNAs in cerebrospinal fluid identify glioblastoma and metastatic brain cancers and reflect disease activity. Neuro-oncology 14, 689-700. doi: 10.1093/neuonc/nos074
72. The ALS Association. (2015). Symptoms and Diagnosis: The ALS Association; 2015 [cited 2015 October 16, 2015]. Available online at: http://www.alsa.org/about-als/symptoms.html
73. van den Boogaard, M., Kox, M., Quinn, K. L., van Achterberg, T., van der Hoeven, J. G., Schoonhoven, L., et al. (2011). Biomarkers associated with delirium in critically ill patients and their relation with long-term subjective cognitive dysfunction; indications for different pathways governing delirium in inflamed and noninflamed patients. Crit Care 15, R297. doi: 10.1186/cc10598
74. van Harten, A., Mulders, J., Çevik, C., Kester, M., Scheltens, P., van der Flier, W., et al. (2011). "MicroRNA analysis in the spinal fluid of Alzheimer patients: a methodological feasibility study, " in Circulating Nucleic Acids in Plasma and Serum, ed P. B. Gahan (Dordrecht: Springer), 275-282.
75. van Munster, B. C., Korevaar, J. C., Zwinderman, A. H., Levi, M., Wiersinga, W. J., and De Rooij, S. E. (2008). Time-course of cytokines during delirium in elderly patients with hip fractures. J. Am. Geriatr. Soc. 56, 1704-1709. doi: 10.1111/j.1532-5415.2008.01851.x
76. Wan, Y., Liu, Y., Wang, X., Wu, J., Liu, K., Zhou, J., et al. (2015). Identification of differential MicroRNAs in cerebrospinal fluid and serum of patients with major depressive disorder. PLoS ONE 10:e0121975. doi: 10.1371/journal.pone.0121975
77. Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., Huang, K. H., Lee, M. J., et al. (2010). The microRNA spectrum in 12 body fluids. Clin. Chem. 56, 1733-1741. doi: 10.1373/clinchem.2010.147405
78. Wei, D., Wan, Q., Li, L., Jin, H., Liu, Y., Wang, Y., et al. (2015). MicroRNAs as potential biomarkers for diagnosing cancers of central nervous system: a meta-analysis. Mol. Neurobiol. 51, 1452-1461. doi: 10.1007/s12035-014-8822-6
79. Xi, Y., Nakajima, G., Gavin, E., Morris, C. G., Kudo, K., Hayashi, K., et al. (2007). Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. RNA 13, 1668-1674. doi: 10.1261/rna.642907
80. Zhu, Y., Li, C., Sun, A., Wang, Y., and Zhou, S. (2015). Quantification of microRNA-210 in the cerebrospinal fluid and serum: implications for Alzheimer's disease. Exp. Ther. Med. 9, 1013-1017. doi: 10.3892/etm.2015.2179
81. Zipser, B. D., Johanson, C. E., Gonzalez, L., Berzin, T. M., Tavares, R., Hulette, C. M., et al. (2007). Microvascular injury and blood-brain barrier leakage in Alzheimer's disease. Neurobiol. Aging. 28, 977-986. doi: 10.1016/j.neurobiolaging.2006.05.016